These findings were recapitulated in two FGFR2-driven endometrial cancer cell lines resistant to the FGFR inhibitor AZD4547 (Figure S2), signifying that this mechanism of PHLDA1 regulation in RTKi resistance is not limited to breast cancer. Here, FGFR2 is linked to endometrial cancer.